These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 17547714)

  • 1. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
    Mangiafico RA; Malaponte G; Pennisi P; Li Volti G; Trovato G; Mangiafico M; Bevelacqua Y; Mazza F; Fiore CE
    J Intern Med; 2007 Jun; 261(6):587-96. PubMed ID: 17547714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
    Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis.
    Jiang LS; Zhang ZM; Jiang SD; Chen WH; Dai LY
    J Bone Miner Res; 2008 Apr; 23(4):475-83. PubMed ID: 18052758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
    J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women.
    Prezelj J; Ostanek B; Logar DB; Marc J; Hawa G; Kocjan T
    Menopause; 2008; 15(2):369-73. PubMed ID: 17882010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.
    Oh KW; Rhee EJ; Lee WY; Kim SW; Oh ES; Baek KH; Kang MI; Choi MG; Yoo HJ; Park SW
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):244-9. PubMed ID: 15272921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density in postmenarchal adolescent girls in the United States: associated biopsychosocial variables and bone turnover markers.
    Harel Z; Gold M; Cromer B; Bruner A; Stager M; Bachrach L; Wolter K; Reid C; Hertweck P; Nelson A; Nelson D; Coupey S; Johnson C; Burkman R; Bone H
    J Adolesc Health; 2007 Jan; 40(1):44-53. PubMed ID: 17185205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry.
    Proudfoot J; Barden A; Mori TA; Burke V; Croft KD; Beilin LJ; Puddey IB
    Anal Biochem; 1999 Aug; 272(2):209-15. PubMed ID: 10415090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
    Spelling P; Bonfá E; Caparbo VF; Pereira RM
    Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.